title: Relationships between serum levels of thyroid hormones and serum concentrations of asymmetric dimethylarginine (ADMA) and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) in patients with Graves' disease.
abstract: Endothelial dysfunction as well as abnormal thyroid hormone levels may be responsible for increased cardiovascular risk in Graves' disease (GD). Asymmetric dimethylarginine (ADMA) and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) are new markers of endothelial and myocardial dysfunction, respectively. The purpose of this study was to investigate the relationship among the serum levels of ADMA, NT-proBNP, and thyroid hormones in GD patients. This was a cross-sectional investigation conducted in a university teaching hospital. Two hundred and thirty-nine GD (Female: 182, Male: 57) patients and 81 normal controls were enrolled in this study. Serum levels of ADMA were positively related with FT3 (r = 0.584, P < 0.001), FT4 (r = 0.551, P < 0.001), and TRAb levels (r = 0.502, P < 0.001). Serum NT-proBNP levels were positively associated with FT3 (r = 0.243, P < 0.001) and FT4 levels (r = 0.274, P < 0.001), as well as heart rate (r = 0.271, P < 0.03). The elevation of serum ADMA and NT-proBNP levels were also observed in patients with controlled hyperthyroidism. It is thus concluded that serum ADMA and NT-proBNP levels were increased in GD patients. Future studies may determine the usefulness of these two biomarkers to detect early signs of endothelial dysfunction, vascular stiffness, and fluid volume in GD patients.
authors.affiliation: Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center For Endocrine and Metabolic Diseases, 197 Rui-jin Er Road, Shanghai, 200025, People's Republic of China.
authors.forename: Li-Qun
authors.initials: LQ
authors.lastname: Gu
authors.forename: Lin
authors.initials: L
authors.lastname: Zhao
authors.forename: Wei
authors.initials: W
authors.lastname: Zhu
authors.forename: Feng-Ying
authors.initials: FY
authors.lastname: Li
authors.forename: Min-Jia
authors.initials: MJ
authors.lastname: Zhang
authors.forename: Yun
authors.initials: Y
authors.lastname: Liu
authors.forename: Jian-Min
authors.initials: JM
authors.lastname: Liu
authors.forename: Guang
authors.initials: G
authors.lastname: Ning
authors.forename: Yong-Ju
authors.initials: YJ
authors.lastname: Zhao
mesh_terms: D000328:Adult; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure; D002318:Cardiovascular Diseases; D003430:Cross-Sectional Studies; D004730:Endothelium, Vascular / Q000503:physiopathology; D005260:Female; D006111:Graves Disease / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D006339:Heart Rate; D006785:Hospitals, University; D006801:Humans; D018828:Immunoglobulins, Thyroid-Stimulating / Q000097:blood; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*; D012307:Risk Factors; D013963:Thyroid Hormones / Q000097:blood*; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
chemical_list: D015415:Biomarkers; D018828:Immunoglobulins, Thyroid-Stimulating; D010446:Peptide Fragments; D013963:Thyroid Hormones; C109794:pro-brain natriuretic peptide (1-76); D014284:Triiodothyronine; D020097:Natriuretic Peptide, Brain; C018524:N,N-dimethylarginine; D001120:Arginine; D013974:Thyroxine